Skip to main content

Table 2 Factors influencing intrahepatic recurrence-free survival and overall survival after stereotactic body radiotherapy

From: Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma

  Intrahepatic recurrence-free survival rates Overall survival rates
  Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Variables HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Gender (male) 0.879 (0.490–1.577) 0.666    0.531 (0.184–1.529) 0.241   
Age 1.021 (0.998–1.045) 0.076 1.025 (1.001–1.049) 0.039 1.024 (0.977–1.074) 0.319   
ECOG performance status (0)a 0.751 (0.403–1.397) 0.365    0.457 (0.147–1.420) 0.176
Child-Pugh class (A) 1.102 (0.699–1.737) 0.677    0.458 (0.259–0.808) 0.007 0.463 (0.262–0.817) 0.008
Viral aetiology (HBV)b 0.928 (0.459–1.877) 0.836    0.440 (0.140–1.382) 0.160
Tumor size 1.006 (0.726–1.393) 0.971    0.863 (0.385–1.938) 0.721   
Alpha-fetoprotein 1.000 (1.000–1.001) 0.628    0.998 (0.990–1.006) 0.664   
PIVKA-II 1.000 (1.000–1.000) 0.448    0.999 (0.995–1.003) 0.712   
No. of prior treatment sessions 1.076 (1.024–1.131) 0.004 1.087 (1.031–1.146) 0.002 0.891 (0.735–1.080) 0.238   
  1. HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, PIVKA-II prothrombin induced by vitamin K absence-II
  2. aCategorical variables are divided as ECOG performance status 0 vs. 1–2
  3. bCategorical variables are divided as HBV (+) vs. HBV (−)